A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
- 00:05Title
- 01:33Preparation of Random Mutation Library by Random Mutagenisis
- 03:38Production of Retroviral Supernatants
- 05:13Selection of Resistant Clones In Vitro
- 08:15In Vitro Validation of Resistant Mutations
- 09:58Results: Identification and Validation of Ruxolitinib Resistant Mutations
- 12:04Concluion
Emergence of genetic resistance against kinase inhibitor therapy poses significant challenge for effective cancer therapy. Identification and characterization of resistant mutations against a newly developed drug helps in better clinical management and next generation drug design. Here, we describe our protocol for in vitro screening and validation of resistant mutations.
